AOD9604 2mg
HGH Fragment for Fat Metabolism Without Insulin Resistance
AOD9604 is the C-terminal fragment of human growth hormone (hGH 177-191) that retains GH's lipolytic activity without affecting blood glucose or insulin signaling, making it an ideal fat-specific research compound.
HGH Fragment for Fat Metabolism Without Insulin Resistance
AOD9604 activates fat cell β3-adrenergic receptors and lipase enzymes to stimulate lipolysis and fat oxidation without the insulin resistance, hypoglycemia, or lean mass effects seen with full-length hGH.
As one of the most studied compounds in the metabolic & fat loss research space, AOD9604 has attracted sustained scientific interest across Fat metabolism research, HGH fragment biology, Adipocyte lipolysis studies. Peer-reviewed evidence indicates that fDA GRAS designation, which has positioned AOD9604 as a reference standard for researchers exploring fat metabolism research outcomes. The compound's selectivity and documented tolerability in preclinical models have contributed to a rapidly growing body of literature over the past decade.
AOD9604 Documented Benefits: 3 Documented Mechanisms
Pure Lipolysis
Stimulates fat breakdown via β3-AR and HSL activation without glucose metabolism effects.
No Insulin Resistance
Unlike full hGH, AOD9604 does not cause insulin resistance or affect blood glucose.
FDA GRAS Status
Designated Generally Recognized As Safe by FDA — one of the best-characterized peptide fragments.
How AOD9604 Works: Molecular Mechanism & Pathway
hGH C-terminal fragment (177-191) activating β3-adrenergic receptors and hormone-sensitive lipase in adipocytes to stimulate lipolysis without growth factor receptor activation.
The 3 primary research pathways identified for AOD9604 — Pure Lipolysis, No Insulin Resistance, FDA GRAS Status — collectively point to a compound with pleiotropic activity across interconnected biological systems. Studies have further shown that stimulates lipolysis without insulin resistance, reinforcing the mechanistic picture established in earlier cell-line work. Unlike single-pathway agents, AOD9604's broad receptor engagement profile continues to generate hypotheses for novel applications beyond its originally characterized use cases.
Research Protocols & Compound Combinations
AOD9604 is routinely studied alongside Semaglutide and AOD9604 in metabolic & fat loss-focused compound panels. Researchers investigating fat metabolism research have found that pairing compounds with complementary receptor profiles can produce additive results while keeping individual doses within well-characterized ranges. Preliminary evidence that clinical trials for obesity and osteoarthritis has informed several of these multi-compound protocol designs.
Purity, Testing & Research Grade Standards
All AOD9604 research material offered through this catalog is manufactured under controlled conditions and independently verified by a third-party laboratory prior to release. Each lot undergoes High-Performance Liquid Chromatography (HPLC) analysis to confirm ≥98% purity, with identity confirmed via mass spectrometry. The accompanying Certificate of Analysis (CoA) documents the exact purity, molecular weight confirmation, and lot-specific testing date — data that should accompany any reproducible research protocol. Lyophilized powder formulation ensures maximum stability during shipping and storage at −20°C long-term or 4°C for short-term use.
◈ Key Highlights
- FDA GRAS designation
- Stimulates lipolysis without insulin resistance
- Clinical trials for obesity and osteoarthritis
Ideal For
- Fat metabolism research
- HGH fragment biology
- Adipocyte lipolysis studies
Intended for laboratory use only. Not for human or animal consumption. Not FDA approved. Handle in appropriate lab settings only.
What the Research Shows
The following data points are derived from peer-reviewed preclinical and clinical studies on AOD9604. All studies cited in compound profiles are indexed in PubMed or published in peer-reviewed journals.
FDA GRAS designation
Stimulates lipolysis without insulin resistance
Clinical trials for obesity and osteoarthritis
Third-Party Verified Every Batch
Each vial of AOD9604 is independently tested by a third-party laboratory before fulfillment. You receive the actual CoA (Certificate of Analysis) documentation with your order.
